Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, looks like 3,000 shares!
Restarting EBOLA program IN NO WAY suggests further delays in the start of FluCide TOX studies!
Today's PR is NOTHING BUT GREAT NEWS! No amount of fanciful thinking and misinterpretation can make it otherwise.
best to all!
NNVC UP OVER 10% PRE MARKET!!!!!
Already printed 4.72!!!!!
ALMOST $18 MILLION SHORT INTEREST= HUGE PRICE SPIKE AHEAD!!!
HUGE 4M SHARE SHORT COVERING RALLY COMING!!!
More short interest means more fuel to the fire for the coming panic short covering rally!
best to all!
EXCELLENT! Thanks! I'll revise my post! /em
45 Institutions Believe the Science: Hold $11M Stock!!!
Intelligent people who direct investments at large institutions actually understand and believe the science of this company. They do not dismiss it out of hand on a whim.
Fourty five institutions now hold over $11M in NNVC stock as of the end of calendar Q1, and these number are expected to grow significantly in the next reporting period basis NanoViricides' recent inclusion into the various Russell Indices, including the important Russell 2000.
http://www.nasdaq.com/symbol/nnvc/institutional-holdings
best to all!
$18 MILLION SHORT INTEREST= HUGE PRICE SPIKE AHEAD!!!
HUGE 4M SHARE SHORT COVERING RALLY COMING!!!
More short interest means more fuel to the fire for the coming panic short covering rally!
best to all!
I'M NEVER WRONG PREDICTING SUCCESS OF A BIOTECH!!!
And NanoViricides will be a HUGE SUCCESS in coming months and years!
I'm never wrong! NEVER!!!
best to all.
Additionally, while Ebola is undeniably hideous, unless the current outbreak gets tragically out of control the commercial potential of an Ebola drug is very limited. By contrast, the market for FluCide is potentially several billion in sales per year.
So, it makes perfect business sense to allocate scarce resources toward the thing that has by far the greatest potential commercial reward.
best to all.
SHORT SQUEEZE STARTED??? ALMOST $18 MILLION SHORT INTEREST!!
HUGE 4M SHARE SHORT COVERING RALLY COMING!!!
More short interest means more fuel to the fire for the coming panic short covering rally!
best to all!
Ridiculous! Each of his transactions were for small amounts, none of which would have been sufficient to affect share price.
The fact that two events occurred at the same time is not evidence of causality. During that period the sun also rose in the east and set in the west every day... so maybe the share price declines were due to the sun?
best to all.
He didn't say that... BECAUSE IT'S NONSENSE! /em
ALMOST $18 MILLION SHORT INTEREST= HUGE PRICE SPIKE AHEAD!!!
HUGE 4M SHARE SHORT COVERING RALLY COMING!!!
More short interest means more fuel to the fire for the coming panic short covering rally!
best to all!
HUGE 4M SHARE SHORT COVERING RALLY COMING!!!
More short interest means more fuel to the fire for the coming panic short covering rally!
best to all!
45 Institutions Believe the Science: Hold $11M Stock!!!
Intelligent people who direct investments at large institutions actually understand and believe the science of this company. They do not dismiss it out of hand on a whim.
Fourty five institutions now hold over $11M in NNVC stock as of the end of calendar Q1, and these number are expected to grow significantly in the next reporting period basis NanoViricides' recent inclusion into the various Russell Indices, including the important Russell 2000.
http://www.nasdaq.com/symbol/nnvc/institutional-holdings
best to all!
No, none of those negative things are true. You have absolutely no factual basis for either statement.
best to all.
Institutions now hold $11M of NNVC stock!
That's the most recent reported number from the end of calendar Q1, so therefore it's PRE RUSSELL INCLUSION! Now that NanoViricides is a member of several Russell indices, including the important Russell 2000, what will the numbers be in the next reporting period? We're at 45 institutional holders now. What will the post-Russell numbers be after mandatory purchases by various tracking funds and other followers of the Russell???
best to all.
http://www.nasdaq.com/symbol/nnvc/institutional-holdings
NONSENSE!!! Here is a real doc's reply to your previous statements regarding the Blood Brain Barrier relative to NNVC drugs.
Member "otodoc" wrote on Friday, 07/18/14 at 03:12:43 PM:
Im a doctor and I find your statements of 'facts' re: the BBB to be nonsense.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104447964&txt2find=BBB
We've been through this issue on this board very recently, and your position has been thoroughly debunked and dismissed, yet here it is all over again.
Repeatedly stating the same falsehood does not cause that falsehood to magically become true.
best to all.
NNVC FluCide's EXCELLENT Pre-Clinical Results Recap!
Lest we forget in the swill of all the opposing points of view, here are snippets from a recent PR which detailed a presentation by company president Diwan to an Influenza Conference earlier in the month. His presentation recapped the EXCELLENT animal trial results from previous studies which form the basis for the push toward human trials for FluCide. THIS is the science. In my opinion THIS is why this company will succeed and why share price will eventually explode.
http://finance.yahoo.com/news/nanoviricides-president-dr-diwan-presented-120000451.html
ALL of the FluCide treated animals survived, while NONE of the non-treated animals survived:
Dr. Diwan discussed the nanoviricides® technology platform, and presented the pre-clinical data on the Company’s first drug candidate, NV-INF-1, Injectable FluCide™, to treat all influenza infections in hospitalized patients. Influenza A H1N1 infected animals treated with FluCide survived the full 21-day observation period, whereas animals treated with 40mg/kg/d oseltamivir phosphate (Tamiflu®) survived only 8 days in this highly lethal study. Influenza A/WS/33/ (H1N1) virus was used in this study. The highly lethal infectious dose of 1M viral particles at time 0 h followed by another 1M virus particles at 23h that was employed caused uniform lethality in 5 days in untreated mice. Body weight began to decline in the infected, untreated mice, by days 2-3 days and continued to decline until death. The Oseltamivir-treated mice maintained body weight only through day 5, which declined thereafter until death. Similar to the survival results, the mice treated with NV-INF-1 maintained their body weight substantially longer, through day 14. NV-INF-1 demonstrated an unparalleled 1,000-fold reduction in lung viral load compared to untreated animals on day 4 in this lethal animal model study.
The pre-clinical safety profile for FluCide is extraordinary, essentially perfect:
Dr. Diwan also discussed the extremely high safety of NV-INF-1 observed in preliminary safety/toxicology studies. He noted that no significant changes in all observed parameters were found even at the maximum feasible dose of approximately 2,700 mg/kg/d repeatedly given for five consecutive days.
The potential market for the company's combined portfolio of drugs once through FDA approval in the coming years is HUGE:
The total market size addressed by the Company’s current drug programs is estimated at about $50 billion. In addition to Injectable FluCide, the Company is working on five more commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well. DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.
-----
The company market cap is currently around $220M. If all drugs succeed through approval in the coming years (not guaranteed), picking a conservative multiplier of five times annual sales, on the high end the company could potentially be valued as high as $250B, for a one thousand times share price appreciation. In that best case scenario, share price under the current post-split structure could be north of $4,000 per share. Or under far more conservative assumptions, maybe share price appreciates only one forth that magnitude, to "only" $1,000 a share? Even reduce that by another factor of four... maybe "only" $250 a share?
Best to all.
This is past ridiculous.
Nonsense! Here is a real doc's reply to your previous statements regarding the Blood Brain Barrier relative to NNVC drugs.
Member "otodoc" wrote on Friday, 07/18/14 at 03:12:43 PM:
Im a doctor and I find your statements of 'facts' re: the BBB to be nonsense.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104447964&txt2find=BBB
We've been through this issue on this board very recently, and your position has been thoroughly debunked and dismissed, yet here it is all over again...
best to all.
NNVC has not paid "stock promoters".
Saying something that's not true 100 times does not make that thing true.
This time next year NNVC will be at least a triple.
Oh, so the accusations are even more ridiculous than we first thought! They were the guys they bought the shell from! No "promotion" of any kind!
best to all.
RIDICULOUS "guilt by association" from 9 years ago!
That's like saying you pay a guy to paint your house, and nine years later that painter guy gets put in prison for something, so somehow now the person who hired the painter nine years ago is guilty of something! WHAT???
Right. And a $6B market cap. So yes, PUMA has clinical results, and the share price and market cap reflect that.
NNVC on the other hand is still a pre-clinical stage company, with a market cap what, about a 1/30th that of PUMA? So the NNVC market cap reflects your observation of no clinical results. And when NNVC enters into clinical trials and registers a few successes, will their market cap grow by 30:1 to match PUMA? I think so, yes.
best to all.
NNVC does NOT associate itself with sleazeball promoters!
That accusation is laughably ridiculous! Wow.
A RIDICULOUS NON-CONNECTION FROM NINE YEARS AGO!!!
Institutions now hold $11M of NNVC stock!
That's the most recent reported number from the end of calendar Q1, so therefore it's PRE RUSSELL INCLUSION! Now that NanoViricides is a member of several Russell indices, including the important Russell 2000, what will the numbers be in the next reporting period? We're at 45 institutional holders now. What will the post-Russell numbers be after mandatory purchases by various tracking funds and other followers of the Russell???
best to all.
http://www.nasdaq.com/symbol/nnvc/institutional-holdings
All this "PAYMENT" Nonsense is Ridiculous Contrived CRAP!
It's so convoluted and preposterous that it's impossible to even follow. It's innuendo and faulty logic and outright falsehoods from as many as eight years ago!
And no one would care even it any of it WERE true!
An opinion website from BULGARIA is laughable "proof".
$14M short will be FUEL TO THE FIRE!!!!!
That's excellent news! There's nothing like panicked traders to capitulate at just the right time to send share prices flying!
Best to all!
NanoViricides' science makes sense to anyone willing to research the facts.
And apparently that includes 45 institutional investors who have place $11M with this company as of the end of calendar Q1 -- with numbers only to grow in the next reporting period basis the company's recent inclusion in the Russell indices.
best to all.
No link. Only 6 Y/O nonsense not backed up with any actual reference.
Meanwhile, institutional investors have put $11M into the company, with more soon to be reported after the Russell inclusion. So which is more important, more relevant, more intelligent? A 6 year old rumor without sourcing or verification, or the actions of 45, yes, FOURTY FIVE institutional investors who collectively have placed $11M in the company?
best.
IT'S SIX YEAR OLD NONSENSE!!!
To your point -- NOT COMPENSATED:
Disclosure
NanoViricides, Inc. is not a client of Ludlow BioVentures. NanoViricides, Inc. has not paid any compensation to Ludlow for inclusion of NNVC in the Ludlow Biotech Index
http://www.businesswire.com/news/home/20080721005782/en/NanoViricides-Added-Ludlow-Biotech-Index#.U87cpOkg9hE
best to all.
NNVC has not hired "Red Chip" or any "pump and dump" firm. They have never paid for promotion, either in cash or in stock.
Best to all.
45 Institutions Believe the Science: Hold $11M Stock!!!
Intelligent people who direct investments at large institutions actually understand and believe the science of this company. They do not dismiss it out of hand on a whim.
Fourty five institutions now hold over $11M in NNVC stock as of the end of calendar Q1, and these number are expected to grow significantly in the next reporting period basis NanoViricides' recent inclusion into the various Russell Indices, including the important Russell 2000.
http://www.nasdaq.com/symbol/nnvc/institutional-holdings
best to all!
NNVC FluCide's EXCELLENT Pre-Clinical Results Recap!
Lest we forget in the swill of all the opposing points of view, here are snippets from a recent PR which detailed a presentation by company president Diwan to an Influenza Conference earlier in the month. His presentation recapped the EXCELLENT animal trial results from previous studies which form the basis for the push toward human trials for FluCide. THIS is the science. In my opinion THIS is why this company will succeed and why share price will eventually explode.
http://finance.yahoo.com/news/nanoviricides-president-dr-diwan-presented-120000451.html
ALL of the FluCide treated animals survived, while NONE of the non-treated animals survived:
Dr. Diwan discussed the nanoviricides® technology platform, and presented the pre-clinical data on the Company’s first drug candidate, NV-INF-1, Injectable FluCide™, to treat all influenza infections in hospitalized patients. Influenza A H1N1 infected animals treated with FluCide survived the full 21-day observation period, whereas animals treated with 40mg/kg/d oseltamivir phosphate (Tamiflu®) survived only 8 days in this highly lethal study. Influenza A/WS/33/ (H1N1) virus was used in this study. The highly lethal infectious dose of 1M viral particles at time 0 h followed by another 1M virus particles at 23h that was employed caused uniform lethality in 5 days in untreated mice. Body weight began to decline in the infected, untreated mice, by days 2-3 days and continued to decline until death. The Oseltamivir-treated mice maintained body weight only through day 5, which declined thereafter until death. Similar to the survival results, the mice treated with NV-INF-1 maintained their body weight substantially longer, through day 14. NV-INF-1 demonstrated an unparalleled 1,000-fold reduction in lung viral load compared to untreated animals on day 4 in this lethal animal model study.
The pre-clinical safety profile for FluCide is extraordinary, essentially perfect:
Dr. Diwan also discussed the extremely high safety of NV-INF-1 observed in preliminary safety/toxicology studies. He noted that no significant changes in all observed parameters were found even at the maximum feasible dose of approximately 2,700 mg/kg/d repeatedly given for five consecutive days.
The potential market for the company's combined portfolio of drugs once through FDA approval in the coming years is HUGE:
The total market size addressed by the Company’s current drug programs is estimated at about $50 billion. In addition to Injectable FluCide, the Company is working on five more commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well. DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.
-----
The company market cap is currently around $220M. If all drugs succeed through approval in the coming years (not guaranteed), picking a conservative multiplier of five times annual sales, on the high end the company could potentially be valued as high as $250B, for a one thousand times share price appreciation. In that best case scenario, share price under the current post-split structure could be north of $4,000 per share. Or under far more conservative assumptions, maybe share price appreciates only one forth that magnitude, to "only" $1,000 a share? Even reduce that by another factor of four... maybe "only" $250 a share?
Best to all.
As long as we don't pass up the opportunity to gratuitously insult management for having guided their little company from the Pink Sheets onto an NYSE exchange and having won inclusion into a prestigious small cap index, then I guess it's OK. Sure, "dumb money". Obviously it's just a fluke to be dismissed, even derided.